CD274 and hepatocellular carcinoma: MerTK drives anti-PD-1/PD-L1 resistance in hepatocellular carcinoma by limiting ferroptosis and promoting an immunosuppressive microenvironment, with its inhibition by sitravatinib enhancing therapy efficacy.